Zynyz 25mg/ml injection,1vial x 20ml(Retifanlimab-dlwr)

Reference priceJPY ¥91,875.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Zynyz
Manufacturer	Incyte Corporation
Prescription required	Yes

Description

Zynyz 25mg/ml injection,1vial x 20ml(Retifanlimab-dlwr) is a medicine catalog record in the MediPriceHub database. Active ingredient: retifanlimab-dlwr. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Incyte Corporation. Therapeutic category: Medicine Library > Oncology Medicines > Cytoma drugs. Pack information: 500 / 20 (25 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) Merkel Cell Carcinoma (MCC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

How to Use

Use retifanlimab-dlwr under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: retifanlimab-dlwr. Pack size: 500 / 20 (25 / ). Pack unit: bottle. Manufacturer: Incyte Corporation. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Cytoma drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。